SG11202111076WA - Therapeutic rna for ovarian cancer - Google Patents

Therapeutic rna for ovarian cancer

Info

Publication number
SG11202111076WA
SG11202111076WA SG11202111076WA SG11202111076WA SG11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA
Authority
SG
Singapore
Prior art keywords
ovarian cancer
therapeutic rna
rna
therapeutic
ovarian
Prior art date
Application number
SG11202111076WA
Other languages
English (en)
Inventor
Ugur Sahin
David Weber
Carina Walter
Roldan Diana Barea
Ruprecht Kuner
Meike Wagner
Martin Suchan
Maurici Stefania Gangi
Stefanie Hubich-Rau
René Becker
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of SG11202111076WA publication Critical patent/SG11202111076WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202111076WA 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer SG11202111076WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019062967 2019-05-20
PCT/EP2020/064180 WO2020234410A1 (en) 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer

Publications (1)

Publication Number Publication Date
SG11202111076WA true SG11202111076WA (en) 2021-11-29

Family

ID=67587718

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111076WA SG11202111076WA (en) 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer

Country Status (15)

Country Link
US (1) US20220257631A1 (ja)
EP (1) EP3972632A1 (ja)
JP (1) JP2022533717A (ja)
KR (1) KR20220010500A (ja)
CN (1) CN114051412A (ja)
AU (1) AU2020277683A1 (ja)
BR (1) BR112021022106A2 (ja)
CA (1) CA3140496A1 (ja)
CL (1) CL2021003063A1 (ja)
CO (1) CO2021016301A2 (ja)
CU (1) CU20210097A7 (ja)
IL (1) IL287554A (ja)
MX (1) MX2021014226A (ja)
SG (1) SG11202111076WA (ja)
WO (1) WO2020234410A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112501201A (zh) * 2021-02-07 2021-03-16 无锡市人民医院 一种用于治疗非小细胞肺癌的rna疫苗及其构建方法
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
TW202333802A (zh) * 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2919567A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences

Also Published As

Publication number Publication date
CL2021003063A1 (es) 2022-10-14
WO2020234410A1 (en) 2020-11-26
IL287554A (en) 2021-12-01
KR20220010500A (ko) 2022-01-25
JP2022533717A (ja) 2022-07-25
CA3140496A1 (en) 2020-11-26
CN114051412A (zh) 2022-02-15
CU20210097A7 (es) 2022-06-06
BR112021022106A2 (pt) 2021-12-28
AU2020277683A1 (en) 2021-11-04
MX2021014226A (es) 2022-01-06
EP3972632A1 (en) 2022-03-30
US20220257631A1 (en) 2022-08-18
CO2021016301A2 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
SG10201913631TA (en) Rna for cancer therapy
IL287554A (en) Rana is therapeutic for ovarian cancer
ZA202005847B (en) Cancer therapy
SG11202101397TA (en) Biomarkers for cancer therapy
GB201903546D0 (en) Cancer treatment
IL287907A (en) Cancer treatment methods
ZA202106392B (en) Therapeutic rna for prostate cancer
GB201905780D0 (en) Cancer therapy
IL282093A (en) Combination therapy for cancer
IL292272A (en) Cancer vaccine
EP3713576A4 (en) CANCER TREATMENT METHODS
IL287652A (en) Cancer treatment
IL284646A (en) Therapeutic RNA for the treatment of solid cancer tumors in advanced stages
IL285466A (en) Cancer treatment
GB201913957D0 (en) Cancer
GB201909468D0 (en) Compounds for treating cancer
GB2580963B (en) Cancer therapies
IL286353A (en) Iademastat combinations for cancer treatment
IL288035A (en) Cancer treatment
IL286680A (en) A drug to treat cancer
EP3981473A4 (en) Therapeutic agent for cancer
EP3847282A4 (en) BIOMARKERS FOR CANCER THERAPY
EP3597197A4 (en) NEW TECHNOLOGY FOR TREATMENT OF CANCER USING STRUCTURALLY REINFORCED S-TUD
EP3344287A4 (en) ANTI-SURVIVIN ANTIBODIES FOR THE TREATMENT OF CANCER
GB201901368D0 (en) Cancer therapy